Kiwi investors help local tech firm on path to improving diagnosis prospects
Potential heart attack or just chest pain?
Upstream Medical Technologies has developed technology that could reduce hospital patient admissions of chest pain by up to 40% and is accelerating to offshore trials following a whirlwind capital raise.
See full article from Stuff.co.nz here
Detecting at-risk heart attack patients, a step closer with $2m investment
Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.
Upstream commences testing Marker C on the APACE cohort
The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.